RPRX
HoldPremium GrowerRoyalty Pharma plc · Healthcare · United States · $35.2B · Avg Vol: $180M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
ABOUT ROYALTY PHARMA PLC
Read
Royalty Pharma plc is a unique healthcare company focused on acquiring royalty interests in marketed and late-stage biopharmaceutical products. The company's competitive moat lies in its specialized business model, offering capital to biopharmaceutical companies in exchange for future royalty payments, thereby de-risking investments in drug development. This strategy provides diversified exposure to blockbuster therapies without direct R&D costs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.2B | 2.4B | 2.3B | 2.4B | 2.1% | 2.5B | 2.6B | 2.8B | 8.2% |
| EPS | 0.10 | 2.54 | 1.93 | 1.80 | 162.0% | 1.86 | 1.99 | 2.14 | 9.0% |
| Shares | 443.2M | 446.7M | 446.0M | 428.7M | -3.3% | 445.3M | — | — | — |
| Debt | 7.1B | 6.1B | 7.6B | 9.0B | 7.9% | 9.0B | — | — | — |
| Equity | 5.6B | 6.5B | 6.9B | 6.5B | 4.8% | — | — | — | — |
| Op CF | 2.1B | 3.0B | 2.8B | 2.5B | 5.1% | 3.0B | — | — | — |
| Inv CF | -1.0B | -2.1B | -2.7B | -1.6B | — | — | — | — | — |
| Fin CF | -944.9M | -2.1B | 361.1M | -1.2B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RPRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RPRX | Royalty Pharma plc(you) | $35.2B | 56 | Hold |
| BMRN | BioMarin Pharmaceutical Inc. | $12.5B | 62 | Hold |
| ALNY | Alnylam Pharmaceuticals, Inc. | $31.7B | 30 | Sell |
| TGTX | TG Therapeutics, Inc. | $8.3B | 61 | Hold |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 70 | Buy |
| MRNA | Moderna, Inc. | $55.1B | 28 | Sell |
| RVMD | Revolution Medicines, Inc. | $44.6B | 23 | Sell |
| CAI | Caris Life Sciences, Inc. | $7.2B | 62 | Hold |
| TVTX | Travere Therapeutics, Inc. | $6.2B | 52 | Hold |
| VRTX | Vertex Pharmaceuticals Incorporated | $137.3B | 68 | Buy |
Peer medians: ROE -31.0% · P/E 25.0x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.